[1] |
LI GF, ZHANG ZY, YANG CM, et al. Classification and action of common hepatoprotective drugs[J]. China Prac Med, 2012, 7(26): 236-238. DOI: 10.14163/j.cnki.11-5547/r.2012.26.212.
黎规丰, 张周英, 杨成密, 等. 常见保肝药的分类及作用[J]. 中国实用医药, 2012, 7(26): 236-238. DOI: 10.14163/j.cnki.11-5547/r.2012.26.212.
|
[2] |
ZHAO RQ, YAO L. Present situation and evaluation of hepatoprotective drugs[J]. J Infect Dis Pharm, 2000, 10(3): 16-18. DOI: 10.13493/j.issn.1672-7878.2000.03.009.
赵汝钦, 么玲. 保肝药的现状和评价[J]. 传染病药学, 2000, 10(3): 16-18. DOI: 10.13493/j.issn.1672-7878.2000.03.009.
|
[3] |
LIU JY, ZHANG CL, LI XP, et al. Utilization analysis of hepatoprotective drugs of 34 hospitals in Wuhan area during 2012-2014[J]. Chin J Pharmacoepidemiol, 2016, 25(2): 113-118. DOI: CNKI:SUN:YWLX.0.2016-02-012.
刘金玉, 张程亮, 李喜平, 等. 2012-2014年武汉地区34家医院保肝药应用分析[J]. 药物流行病学杂志, 2016, 25(2): 113-118. DOI: CNKI:SUN:YWLX.0.2016-02-012.
|
[4] |
National Health Commission of the People's Republic of China, Medical Administration and Medical Authorit. Notice on the management of clinical application of adjuvant drugs [EB/OL]. [2018-12-12] (2020-08-27). http://www.nhc.gov.cn/yzygj/s7659/201812/bc0259007f1a4cf38cb5d0352470e33e.shtml'2018
国家卫生健康委员会, 医政医管局. 关于做好辅助用药临床应用管理有关工作的通知[EB/OL]. [2018-12-12] (2020-08-27). http://www.nhc.gov.cn/yzygj/s7659/201812/bc0259007f1a4cf38cb5d0352470e33e.shtml'2018
|
[5] |
Chinese Society of Infectious Diseases, Expert Consensus Committee on Liver Inflammation and Its Prevention and Treatment. Prevention and management of liver inflammation: An expert consensus in China[J]. Chin J Clin Infect Dis, 2014, 7(1): 4-12. DOI: 10.3760/cma.j.issn.1674-2397.2014.01.002.
中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中华临床感染病杂志, 2014, 7(1): 4-12. DOI: 10.3760/cma.j.issn.1674-2397.2014.01.002.
|
[6] |
CAO M, LI X, ZHANG B, et al. The effect of polyene phosphatidyl choline intervention on nonalcoholic steatohepatitis and related mechanism[J]. Am J Transl Res, 2016, 8(5): 2325-2330.
|
[7] |
WEN XL, ZHANG HL. Literature anaiysis of adverse reactions caused by poiyene phosphatidyi choiine [J]. Chin J Pharmacov, 2020, 17(8): 526-530. DOI: 10.19803/j.1672-8629.2020.08.16.
文晓玲, 张海浪. 多烯磷脂酰胆碱不良反应文献分析[J]. 中国药物警戒, 2020, 17(8): 526-530. DOI: 10.19803/j.1672-8629.2020.08.16.
|
[8] |
YANG YL, ZHANG ZQ, WEI YQ. Clinical study on silybinin combined with polyene phosphatidylcholine for nonalcoholic fatty liver disease[J]. J New Chin Med, 2020, 52(18): 81-84. DOI: 10.13457/j.cnki.jncm.2020.19.023.
杨亚莉, 张志强, 魏毅强. 水飞蓟宾联合多烯磷脂酰胆碱治疗非酒精性脂肪肝临床研究[J]. 新中医, 2020, 52(18): 81-84. DOI: 10.13457/j.cnki.jncm.2020.19.023.
|
[9] |
CHEN JH, XU YM. Clinical effect of polyene phosphatidylcholine combined with metformin in the treatment of non-alcoholic fatty liver disease [J]. Chronic Pathematol J, 2020, 21(6): 885-886. DOI: 10.16440/j.cnki.1674-8166.2020.06.031.
陈建辉, 许亚妹. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝临床效果[J]. 慢性病血杂志, 2020, 21(6): 885-886. DOI: 10.16440/j.cnki.1674-8166.2020.06.031.
|
[10] |
CHENG ZH. Clinical effect of polyene phosphatidylcholine combined with reduced glutathione in the treatment of alcoholic hepatitis [J]. Chin J Med Devi, 2020, 33(19): 115-116. DOI: 10.14163/J.CNKI.11-5547/R.2015.09.112.
程灶鸿. 多烯磷脂酰胆碱联合还原型谷胱甘肽治疗酒精性肝炎患者的临床效果[J]. 医疗装备, 2020, 33(19): 115-116. DOI: 10.14163/J.CNKI.11-5547/R.2015.09.112.
|
[11] |
LI CY, SHI YH. Effect of polyene phosphatidylcholine on liver fibrosis and liver function of alcoholic fatty liver[J]. Hainan Med J, 2020, 31(13): 1649-1651. DOI: 10.3969/j.issn.1003-6350.2020.13.004.
李传元, 石益海. 多烯磷脂酰胆碱对酒精性脂肪肝肝纤维化及肝功能的影响[J]. 海南医学, 2020, 31(13): 1649-1651. DOI: 10.3969/j.issn.1003-6350.2020.13.004.
|
[12] |
XU H, GAO ZW, LIU JX, et al. Effect of polyene phosphatidylcholine on liver fibrosis and liver function of alcoholic fatty liver [J]. Hainan Med J, 2018, 15(4): 164-167. DOI: 10.3969/j.issn.1003-6350.2020.13.004.
徐辉, 高志文, 刘健许, 等. 多烯磷脂酰胆碱胶囊联合还原型谷胱甘肽治疗抗结核药物致肝损伤患者的临床疗效[J]. 实用医院临床杂志, 2018, 15(4): 164-167. DOI: 10.3969/j.issn.1003-6350.2020.13.004.
|
[13] |
SHI L. Analysis of the effects of polyene phosphatidylcholine combined with silybin on liver function and blood lipid levels in patients with chronic hepatitis B[J]. Chin J Pharm Econom, 2020, 15(5): 94-97. DOI: 10.12010/j.issn.1673-5846.2020.05.021.
时岚. 多烯磷脂酰胆碱联合水飞蓟宾对慢性乙型肝炎患者肝功能及血脂水平的影响[J]. 中国药物经济学, 2020, 15(5): 94-97. DOI: 10.12010/j.issn.1673-5846.2020.05.021.
|
[14] |
SHANG YH. Efficacy of bicyclol combined with polyene phosphatidylcholine in the treatment of hyperthyroid liver injury [J]. Chin J Modern Drug Appl, 2020, 14(4): 9-11. DOI: 10.14164/j.cnki.cn11-5581/r.2020.04.004.
尚月华. 双环醇联合多烯磷脂酰胆碱治疗甲亢性肝损伤的疗效观察[J]. 中国现代药物应用, 2020, 14(4): 9-11. DOI: 10.14164/j.cnki.cn11-5581/r.2020.04.004.
|
[15] |
XIE W, YU YC. Expert consensus on clinical application of bicyclol—2020 edition [J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2020, 14(3): 177-185. DOI: 10.3877/cma.j.issn.1674-1358.2020.03.001.
谢雯, 于乐成. 双环醇临床应用专家共识——2020版[J/CD]. 中华实验和临床感染病杂志(电子版), 2020, 14(3): 177-185. DOI: 10.3877/cma.j.issn.1674-1358.2020.03.001.
|
[16] |
LI H, LI JR, HUANG MH, et al. Bicyclol attenuates liver inflammation induced by infection of hepatitis C virus via repressing ROS-mediated activation of MAPK/NF-κB signaling pathway[J]. Front Pharmacol, 2018, 9: 1438. DOI: 10.3389/fphar.2018.01438.
|
[17] |
LIU JL, BAI YM, TIAN GS. Progress in the application of compound glycyrrhizin in liver diseases [J]. Chin Pharm, 2006, 23: 1828-1830. DOI: 10.3969/j.issn.1001-0408.2006.23.031.
刘君澜, 白永敏, 田庚善. 复方甘草酸苷在肝病领域的应用进展[J]. 中国药房, 2006, 23: 1828-1830. DOI: 10.3969/j.issn.1001-0408.2006.23.031.
|
[18] |
DU DF, WANG RZ. Efficacy of compound glycyrrhizin with narrow-band ultraviolet radiation in the treatment of psoriasis vulgaris and its effect on cytokines and proliferation genes[J]. J Clin Exp Med, 2020, 19(3): 307-310. DOI: 10.3969/j.issn.1671-4695.2020.03.024.
杜聃峰, 汪睿志. 复方甘草酸苷联合NB-UVB治疗寻常性银屑病的疗效及对细胞因子和增殖基因的影响[J]. 临床和实验医学杂志, 2020, 19(3): 307-310. DOI: 10.3969/j.issn.1671-4695.2020.03.024.
|
[19] |
WU P. Analysis on the use of hepatoprotective drugs in inpatients in our hospital[J]. Clin Ration Drug Use, 2020, 13(2A): 109-110. DOI: 10.15887/j.cnki.13-1389/r.2020.04.063.
吴璠. 我院住院患者保肝药使用情况分析[J]. 临床合理用药, 2020, 13(2A): 109-110. DOI: 10.15887/j.cnki.13-1389/r.2020.04.063.
|
[20] |
National Healthcare Security Administration, Ministry of Human Resources and Social Security of the People's Republic of China. "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue (2020)" [EB/OL]. [2020-12-25] (2021-03-30). http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html
国家医保局, 人力资源社会保障部. 《国家基本医疗保险、工伤保险和生育保险药品目录(2020年)》的通知[EB/OL]. [2020-12-25] (2021-03-30). http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html
|